Skip to main content

Advertisement

Table 3 Patient characteristics and expression of pS 21 GSK3α, pS 9 GSK3β, cyclin D1 and P53 in oral cancer and control tissue samples

From: Expression and inactivation of glycogen synthase kinase 3 alpha/ beta and their association with the expression of cyclin D1 and p53 in oral squamous cell carcinoma progression

Sl. No. Groups Total (n = 39) Samples showing the positive expression of proteins (n)
Cyclin D1 P53 pS 21 GSK3α pS 9 GSK3β
1 Age      
 ≤40 23 17 (73.9%) 08 (34.7%) 12 (52.1%) 14 (60.8%)
 >40 ≤ 70 16 08 (50.0%) 08 (50.0%) 10 (62.5%) 09 (56.2%)
2 Sex      
   Male 23 14 (60.8%) 10 (43.4%) 13 (56.5%) 14 (60.8%)
   Female 16 11 (68.7%) 06 (37.5%) 09 (56.2%) 09 (56.2%)
3 Histological grade/Tumour Progression      
   Normal 6 00 (00.0%) 01 (16.6%) 00 (00.0%) 00 (00.0%)
   PML 6 06 (100%) 03 (50.0%) 01 (16.6%) 02 (33.3%)
   WDSCC 15 10 (66.6%) 07 (46.6%) 10 (66.6%) 11 (73.3%)
   MDSCC 6 06 (100%) 05 (83.3%) 06 (100%) 05 (83.3%)
   PDSCC 6 03 (50.0%) 01 (16.6%) 05 (83.3%) 05 (83.3%)
4 Tobacco History      
   Yes 23s 14 (60.8%) 11 (47.8%) 12 (52.1%) 13 (56.5%)
   No 16 11 (68.7%) 05 (31.2%) 10 (62.5%) 10 (62.5%)
5 pS 21 GSK3α Expression      
   Positive 22 18 (81.8%) 12 (54.5%) 22 (100%) 20 (90.9%)
   Not-Positive 17 07 (41.1%) 04 (23.5%) 00 (00.0%) 03 (17.6%)
6 pS 9 GSK3β Expression      
   Positive 23 18 (78.2%) 11 (47.8%) 20 (86.9%) 23 (100%)
   Not Positive 16 07 (43.7%) 05 (31.2%) 02 (12.5%) 00 (00.0%)